Home
overview

Partnerships are vital to the business of drug development. As pipelines become sparser, companies need to work together to access the appropriate molecules, expertise, and funding to maximise their potential. Pharmaceutical Collaborations 2008 will showcase presentations from top speakers on all aspects of partnering.

  • Hear case studies from the different the parties to collaborations
  • Learn about techniques of alliance management and metrics for valuing collaboration
  • Discover how collaborations with Universities function - from thier perspective 
  • Understand your contractual obligations, and reimbursement opportunities
  • Network with key decision makers in an environment dedicated to collaboration

New Speaker Confirmed:

  • Chris Piggott, Consultant, Medius Associates, former Vice President, Sanofi Aventis

Our other confirmed speakers include:

  • Christian Clauss, Global Director, Regulatory Affairs New Product Development, Bioscience, Baxter World Trade
  • Bruce Pratt, Vice President, Science Development, Genzyme
  • Ray Hill, Executive Director and Head, Licensing and External Research, Europe, Merck, Sharpe and Dohme
  • Esteban Pombo-Villar, Head of Strategic Alliance Management EU, Novartis
  • Chris Henderson, Executive Transaction Director, Strategic Planning Business Development, AstraZeneca
  • Rob Hockney, Director, Alliance Management, AstraZeneca
  • Brooke Paige, Director, Strategic Alliance Management, Boehringer Ingelheim
  • Timothy Herpin, Director, Metabolic Disease Licencing, Bristol Myers Squibb
  • Paul Clewlow, Senior Vice President, Business Development, Argenta Discovery
  • Brian O’Neill, Global Head, QCA External Alliances, F-Hoffmann-La Roche
  • Jeff Southerton, Executive Director - Head, Theraputic Area Strategic Alliances, Pfizer
  • Ken Douglas, Professor of Medicinal Chemistry, University of Manchester
  • Simon Portman, Partner, Hewitson’s Solicitors
  • Loic Kubitza, Assistant Director, Market and Value Advisory, PricewaterhouseCoopers

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Ray Hill

Ray Hill, Executive Director, Licensing & External Research, Merck Sharp & Dohme

9:10 OPENING KEYNOTE

Bruce Pratt

Bruce Pratt, Vice President, Science Development, Genzyme Corporation

  • Contemporary tendencies in mergers and acquisitions, collaborations and the pharma market more broadly
  • Where are the collaborations happening now; Phase I, II, III, or pre-clinical?
  • The current trends in reimbursement and funding
  • Results of a possible downturn in mergers and acquisitions
  • Collaborations in the context of the pharma and biotech markets
  • 9:50 FINDING THE RIGHT PARTNERSHIP

    Ray Hill

    Ray Hill, Executive Director, Licensing & External Research, Merck Sharp & Dohme

  • What are you trying to get done?
  • The capabilities and limitations of the various potential partners: Big pharma, Small pharma/biotechs, Universities, CROs, and Technology providers
  • 10:30 Morning Coffee

    11:00 STRATEGIC OR TACTICAL COLLABORATION? – A ROUND TABLE DISCUSSION

  • What’s the difference
  • What are the positives to a long term strategic collaboration
  • When is a short term relationship preferable?
  • What can happen when parties have different long term objectives
  • Rob Hockney

    Rob Hockney, Director, Alliance Management, AstraZeneca

    Bruce Pratt

    Bruce Pratt, Vice President, Science Development, Genzyme Corporation

    Paul Clewlow

    Paul Clewlow, Senior Vice President, ARGENTA DISCOVERY

    Timothy Herpin

    Timothy Herpin, Director, Bristol-Myers Squibb

    11:40 RESEARCH AND EARLY STAGE COLLABORATIONS AT BRISTOL MYERS SQUIBB: RECENT CASE STUDIES

    Timothy Herpin

    Timothy Herpin, Director, Bristol-Myers Squibb

  • Recent research collaborations
  • Levaraging both parties expertise and capabilities
  • Creative deal structures
  • 12:20 Networking Lunch

    13:50 COLLABORATIONS WITH CROs – CASE STUDY

    Paul Clewlow

    Paul Clewlow, Senior Vice President, ARGENTA DISCOVERY

  • Why outsource drug discovery?
  • What are the expectations from their service-providers?
  • Cultural and capability differences
  • Potential points of friction
  • Case History: Integrated drug discovery programme – from hit ID to development candidate
  • 14:30 COLLABORATIONS WITH UNIVERSITIES – CASE STUDY

    Ken Douglas

    Ken Douglas, Professor of Medicinal Chemistry, The University Of Manchester

  • A university's perspective
  • The benefits of collaboration from the perspective of universities
  • Points of tension and examples of success
  • Specific examples from a case study
  • 15:10 Afternoon Tea

    15:40 TECHNICAL ASSESSMENT AND DUE DILIGENCE FOR A PHARMACEUTICAL DEAL - A NEW APPROACH

  • Hurdles and key issues for the assessment of new projects and duediligence
  • How to best organize the process
  • Risk management a balanced net present value
  • Cases studies from realities
  • What’s new ?
  • Importance of proof of concept
  • Gunther Busam

    Gunther Busam, TRD, Drug Supply Management, Head Global Outsourcing Management, Novartis A G

    Louis-Christian Clauss

    Louis-Christian Clauss, Global Director, Regulatory Affairs New Product Development, BioScience, Baxter World Trade

    16:20 VALUING PHARMACEUTICAL DEALS

    Loic Kubitza

    Loic Kubitza, Assistant Director, PricewaterhouseCoopers

  • Trends in pharmaceutical deal activity
  • Choosing between upfront payments, milestones and royalties
  • Using market comparables or discounted cash flow analysis
  • A review of valuation methodologies
  • Strategies for value creation
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Esteban Pombo-Villar

    Esteban Pombo-Villar, Head, Novartis A G

    9:10 OPENING KEYNOTE- THE METRICS OF COLLABORATIONS

    Brooke Paige

    Brooke Paige, Director, Boehringer Ingelheim Pharm Inc, SCIS

  • Auditing the progress and success of collaborations
  • Organisational metrics and Outcomes metrics
  • Intangible benefits – how a scientific failure can also be a successful partnership
  • Putting a price on partnership – rational valuations of collaborations
  • 9:50 THE SECRETS OF SUCCESSFUL ALLIANCE MANAGEMENT

    Esteban Pombo-Villar

    Esteban Pombo-Villar, Head, Novartis A G

  • Establishing trust between the parties
  • Monitoring the health of a relationship
  • Clear divisions of responsibilities and good communication ensure a successful collaboration
  • Real world examples of partnering challenges – and their solutions
  • 10:30 Morning Coffee

    11:00 POTENTIAL PITFALLS IN ALLIANCES

    Chris Henderson

    Chris Henderson, Executive Director Strategic Planning & Business Development, AstraZeneca Corporate Office

  • The warning signs – things to look out for in choosing a potential partner
  • Differing expectations and cultures as a cause of trouble
  • If a partnership goes wrong, how do you get out?
  • 11:40 EXPERIENCES OF ALLIANCE MANAGEMENT - ROUND TABLE DISCUSSION

  • Contributions from participants on thier perspectives
  • Esteban Pombo-Villar

    Esteban Pombo-Villar, Head, Novartis A G

    Brooke Paige

    Brooke Paige, Director, Boehringer Ingelheim Pharm Inc, SCIS

    Jeff Southerton

    Jeff Southerton, Director, Strategic Alliances, Global R&D, Pfizer

    Paul Clewlow

    Paul Clewlow, Senior Vice President, ARGENTA DISCOVERY

    Chris Henderson

    Chris Henderson, Executive Director Strategic Planning & Business Development, AstraZeneca Corporate Office

    12:20 Networking Lunch

    13:50 MANAGING DEALS INTERNATIONALLY

    Jeff Southerton

    Jeff Southerton, Director, Strategic Alliances, Global R&D, Pfizer

  • Many of Pfizer's collaborations involve stakeholders in numerous parts of the world
  • Negotiating and managing relationships between the various parties spread across timezones
  • 14:30 COLLABORATIONS IN EMERGING MARKETS

    Chris Piggott

    Chris Piggott, Consultant, Medius Associates Ltd

    15:10 Afternoon Tea

    15:40 CONTRACTS AND LEGAL REQUIREMENTS

    Simon Portman

    Simon Portman, Partner, Hewitson Solicitors

  • The range of contractual possibilities open to the parties
  • How not to be caught out in contractual negotiations
  • Cross border collaborations – legal and cultural differences in different markets
  • 16:20 Chairman’s Closing Remarks and Close of Day Two

    +

    Workshops

    The tool-kit for successful collaborations - new developments and opportunities
    Workshop

    The tool-kit for successful collaborations - new developments and opportunities

    The Hatton, at etc. venues
    19th February 2008
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.